Ebumnobi anyị bụ isi mgbe niile bụ inye ndị ahịa anyị ezigbo mmekọrịta obere azụmaahịa dị mkpa, na-enye nlebara anya nkeonwe nye ha niile maka mmamịrị - ngwa,enwe nkwusioru Hepatocytes ngwa, ngwa mmiri ara oke oke, ngwa imeju lysosomes òké, Ngwakọta sel mononuclear splin. Ugbu a, anyị na-atụ anya ka anyị na ndị ahịa si mba ofesi na-emekọ ihe ọnụ na-adabere na uru ọ bụla. Biko nweere onwe gị ịkpọtụrụ anyị maka nkọwa ndị ọzọ. Anyị factory na-ekwusi ike na ụkpụrụ nke "Quality First, Sustainable Development", na-ewe "Eziokwu Business, Mutual Uru" dị ka anyị developmentable mgbaru ọsọ. Ndị otu niile na-ekele ekele maka nkwado ndị ahịa ochie na ndị ọhụrụ. Anyị ga na-agbasi mbọ ike ma na-enye gị ngwaahịa na ọrụ kacha mma. Daalụ.ngwa ngalaba oyi kpọnwụrụ, ngwa cytosol akpa ume, ngwa CD14+ òké, kit homogenate akpa ume.
Antibody - Drug Conjugate (ADC) bụ ụdị ọgwụ biotechnology ọhụrụ nke na-ejikọ obere ogige ọgwụgwọ molecule na-ezubere iche mgbochi mgbochi / mgbochi mgbochi site na njikọ.
N'oge na-adịbeghị anya, IPHASE, yana njikọ Perelman School of Medicine na University of Pennsylvania, dere otu isiokwu na akwụkwọ akụkọ Antibody Therapeutics (IF=4.56) nke akpọrọ "Development of a
Ụdị nyocha PDC in vitro ADME PDC na-eburu n'uche njirimara nke ma nnukwu ma obere ụmụ irighiri ihe. Ya mere, in vitro ADME nyocha na ya kwesịrị iburu n'uche peptides homing, njikọ
The in vivo alkaline comet assay ka ejirila na-enyocha ihe omimi nke ogige. ICH S2 (R1) agụnyela imeju comet assay dị ka 2nd in vivo test for tissues/ endpoints; ihe
C57BL/6, nke a na-akpọkarị "C57 black 6", "C57", ma ọ bụ "black 6" (ụkpụrụ abbreviation B6), bụ ụdị òké ụlọ nyocha. A na-ejikarị ya dị ka òké transgenic na nyocha mkpụrụ ndụ ihe nketa iji ṅomie ntụpọ mkpụrụ ndụ ihe nketa mmadụ.